Cobalt Cardiomyopathy Secondary to Hip Arthroplasty: An Increasingly Prevalent Problem

Russel Tilney1, Melanie Roberta Burg2, Mark Adrian Sammut2

  • 1Department of Medicine, Mater Dei Hospital, Msida, Malta.

Insights

Metal-on-metal hip implants can release cobalt, causing heart failure. Revision surgery to replace the implant resolved the patient's symptoms and improved heart function.

Area of Science:

  • Biomaterials Science
  • Cardiology
  • Toxicology

Background:

  • Total hip replacement with metal-on-metal components can lead to adverse local tissue reactions and systemic toxicity.
  • Cobalt-chromium alloys are commonly used in hip arthroplasty, raising concerns about ion release and systemic effects.

Observation:

  • A patient presented with worsening heart failure four years after bilateral complicated total hip replacement.
  • Elevated cobalt blood levels and clinical presentation suggested implant-related toxicity.
  • Intraoperative findings revealed biotribocorrosion on the hip arthroplasty components.

Findings:

  • Revision surgery of the affected hip led to significant symptomatic improvement in heart failure (NYHA class III to I).
  • Echocardiography demonstrated recovery of ejection fraction post-revision.
  • Cobalt ions, similar to nanoparticles, exhibit cytotoxicity affecting neurological, thyroid, and cardiac systems.

Implications:

  • Cobalt-induced cardiomyopathy is a potential complication of metal-on-metal hip arthroplasty.
  • Arthroplasty revision is the definitive treatment for cobalt toxicity, as other therapies are unproven.
  • Monitoring cobalt blood levels requires careful interpretation due to independent erythrocyte and serum dynamics.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
553
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
632
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
677
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
648
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
510
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
382